Switzerland - HealthQuill

Anglo-Swedish AstraZeneca Plc., and Japan’s Daiichi Sankyo’s therapy to treat a certain form of breast cancer has been approved by the US drug regulator in the adult population.

AstraZeneca-Daiichi’s breast cancer drug gets broader US nod

Anglo-Swedish AstraZeneca Plc., and Japan’s Daiichi Sankyo’s therapy to treat a certain form of breast cancer has been approved by the US drug.

by HealthQuill
January 28, 2025
0 Comments

Switzerland’s F. Hoffmann-La Roche AG will buy US-based biopharmaceutical company Poseida Therapeutics for $1.5 billion, according to a statement from the Basel-headquartered company.

Drugs Health Pharma

Roche to acquire US-based Poseida Therapeutics for $1.5 billion

Switzerland’s F. Hoffmann-La Roche AG will buy US-based biopharmaceutical company Poseida Therapeutics for $1.5 billion, according to a statement from the Basel-headquartered company.

by HealthQuill
November 26, 2024
0 Comments

British-Swedish AstraZeneca’s drug for treatment of a form of blood cancer has been granted a Priority Review in the US by the drug regulator.

Drugs Health Pharma

AstraZeneca’s experimental blood cancer drug gets US priority review

British-Swedish AstraZeneca’s drug for treatment of a form of blood cancer has been granted a Priority Review in the US by the drug.

by HealthQuill
October 3, 2024
0 Comments

Switzerland’s Basilea Pharmaceutica Ltd. will receive $1.25 million from its partner Pfizer Inc. after the latter exceeded the sales target for a licensed anti-fungal drug in the Asia-Pacific region and China.

Drugs Medical Pharma

Basilea Pharmaceutica to get $1.25m license fee from Pfizer

Switzerland’s Basilea Pharmaceutica Ltd. will receive $1.25 million from its partner Pfizer Inc. after the latter exceeded the sales target for a licensed.

by HealthQuill
August 21, 2024
0 Comments

Ascidian Therapeutics, a US-based biotechnology company announced a $42 million research pact with Swiss multinational Roche AG for developing gene editing therapies.

Drugs Health Pharma

Roche to pay $42 million to Ascidian to make RNA exon editing drugs

Ascidian Therapeutics, a US-based biotechnology company announced a $42 million research pact with Swiss multinational Roche AG for developing gene editing therapies.

by HealthQuill
June 18, 2024
0 Comments

Cordis, a US-based medical device maker, has acquired Switzerland’s MedAlliance for up to $1.1 billion to expand its product portfolio.

Health Medical Pharma

Cordis acquires medical device maker MedAlliance for $1.1 billion

HQ Team October 2, 2023: Cordis, a US-based medical device maker, has acquired Switzerland’s MedAlliance for up to $1.1 billion to expand its.

by HealthQuill
October 2, 2023
0 Comments

Swiss researchers revealed that the artificial cooling of climate through geo-engineering will not work without decarbonization and involves high risks.

Climate Health Pharma

‘Dimming of sun’ to save Antarctic ice fraught with dangers

HQ Team August 14, 2023: The artificial cooling of climate through geo-engineering will not work without decarbonization and involves high risks, Swiss researchers.

by HealthQuill
August 14, 2023
0 Comments

Any hobby with a personal meaning can ward off loneliness, a joint study found.

Health Medical Pharma

Hobby with a personal meaning can fight loneliness, says study

HQ Team June 27, 2023: Any hobby with a personal meaning can ward off loneliness, a joint study found. “Loneliness are known to.

by HealthQuill
June 27, 2023
0 Comments

Swiss drugmaker, Novartis signed a $3.5 billion deal with Chinook Therapeutics to boost the US-based company’s last-stage experimental trials of two drugs to treat chronic kidney diseases.

Drugs Health Pharma

Novartis to acquire Chinook Therapeutics in a $3.5 billion deal

HQ Team June 13, 2023: Swiss drugmaker, Novartis signed a $3.5 billion deal with Chinook Therapeutics to boost the US-based company’s last-stage experimental.